Plain-English translation of NCT05976763 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called (given alongside another drug called ) to treat older patients with mantle cell lymphoma who have never received treatment before. The main question is whether it works better to take the medication continuously for as long as possible, or to take it initially, stop when the disease is under control, and restart it only if the disease comes back.
Doctors want to find the best balance for older patients: keeping the disease controlled while also reducing the burden of taking medication long-term and managing side effects. This medication is promising for mantle cell lymphoma, but no one yet knows whether continuous or intermittent treatment produces better outcomes for older patients.
You likely qualify if…
You likely don't qualify if…
You will first receive combination therapy with the two medications ( and ) for induction. After that, you will be randomly assigned to one of two groups: either you continue taking the medication continuously until the disease progresses, or you stop treatment and are monitored with regular scans and blood work, restarting the medication only if the disease returns. Throughout the trial, you will have regular imaging scans (CT, PET, or MRI), blood tests, possible bone marrow biopsies, and questionnaires about how you are feeling and your quality of life. The trial enrollment is 421 patients.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States